ABC transporter-mediated multidrug-resistant cancer

H Amawi, HM Sim, AK Tiwari, SV Ambudkar… - Drug Transporters in …, 2019 - Springer
ATP-binding cassette (ABC) transporters are involved in active pumping of many diverse
substrates through the cellular membrane. The transport mediated by these proteins …

The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer

M Heger, RF van Golen, M Broekgaarden… - Pharmacological …, 2014 - ASPET
This review addresses the oncopharmacological properties of curcumin at the molecular
level. First, the interactions between curcumin and its molecular targets are addressed on …

Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies

CM Hattinger, MP Patrizio, L Fantoni, C Casotti… - Cancers, 2021 - mdpi.com
Simple Summary Despite the adoption of aggressive, multimodal treatment schedules, the
cure rate of high-grade osteosarcoma (HGOS) has not significantly improved in the last 30 …

Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future

SPC Cole - Annual review of pharmacology and toxicology, 2014 - annualreviews.org
The human ATP-binding cassette transporter multidrug resistance protein 1 (MRP1),
encoded by ABCC1, was initially identified because of its ability to confer multidrug …

Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies

L Amiri-Kordestani, A Basseville, K Kurdziel… - Drug Resistance …, 2012 - Elsevier
This special issue of Drug Resistance Updates is dedicated to multidrug resistance protein 1
(MDR-1), 35 years after its discovery. While enormous progress has been made and our …

The therapeutic potential of targeting ABC transporters to combat multi-drug resistance

P Bugde, R Biswas, F Merien, J Lu, DX Liu… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Most disseminated cancers remain fatal despite the availability of a variety of
conventional and novel treatments including surgery, chemotherapy, radiotherapy …

Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells

S Wu, L Fu - Molecular cancer, 2018 - Springer
Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …

[HTML][HTML] Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives

A Elfadadny, HM El-Husseiny, A Abugomaa… - … Science and Pollution …, 2021 - Springer
Cancer, a major public health problem, is one of the world's top leading causes of death.
Common treatments for cancer include cytotoxic chemotherapy, surgery, targeted drugs …

[HTML][HTML] Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy

W Xu, C Ye, X Qing, S Liu, X Lv, W Wang, X Dong… - Materials Today Bio, 2022 - Elsevier
Abstract Multi-target Tyrosine Kinase Inhibitors (MTKIs) have drawn substantial attention in
tumor therapy. MTKIs could inhibit tumor cell proliferation and induce apoptosis by blocking …

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

S Shukla, ZS Chen, SV Ambudkar - Drug resistance updates, 2012 - Elsevier
Tyrosine kinases (TKs) are involved in key signaling events/pathways that regulate cancer
cell proliferation, apoptosis, angiogenesis and metastasis. Deregulated activity of TKs has …